$612 | SAVE $83 | Single User
$1228 | SAVE $167 | Global License

Physician Views: Is the HER2-positive breast cancer extended adjuvant opportunity big enough to support neratinib's blockbuster forecasts?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 28 Jul 2014 | 142 | In Stock
Related Topics: Biotechnology , Pfizer , Roche

Introduction

Scope



Top-line data from the ExteNET study – which were released earlier this week – appear to establish Puma Biotechnology's neratinib as a viable therapy for use in the extended adjuvant setting for HER2-positive breast cancer. Data indicates that treatment with neratinib for 12 months following standard 12-month therapy with Herceptin increases disease-free survival by 33 percent versus placebo.


Significantly, there appear to be no other products in development for usage in this setting. With Roche's Herceptin generating annual sales of around billion in the adjuvant setting, analysts have been quick to ascribe blockbuster potential to neratinib – see ViewPoints: Puma's perfect storm - share price triples on new breast cancer data.


The data come as something of a surprise. Partly as the ExteNET study is a legacy of Pfizer's development of neratinib (Puma in-licensed the compound in 2011 and have primarily focused on its development in neo-adjuvant HER2-positive breast cancer) and partly as previous efforts to extend duration of therapy in adjuvant patients have delivered less than compelling data.


Most notably, the HERA study failed to demonstrate any benefit from extending adjuvant therapy with Herceptin from one to two years. Nevertheless, this has not prevented some commentators from arguing that a more valid study design would be to compare a combination of neratinib and Herceptin to Herceptin monotherapy during a second year of adjuvant therapy (rather than compare neratinib to placebo as the ExteNET study does). Puma has partially defended the study design by suggesting that neratinib has demonstrated effectiveness in patient subsets where Roche's newer HER2 therapies Perjeta and Kadcyla have not. This could differentiate the product and thus ensure longer-term use in the extended adjuvant setting even if Roche is successful in shifting the standard of care for adjuvant patients via its two newer therapies.


Puma is also yet to unveil any safety data from ExteNET, but has cautioned that the rate of grade 3 diarrhoea could be as high as 30 percent. In subsequently initiated studies of neratinib, Puma has employed Imodium prophylaxis to combat this side effect and hopes to reduce the rate to between 5 percent and 10 percent in a real-world setting.


Puchase Reasons


To initially ascertain the commercial opportunity for neratinib based on top-line data from ExteNET, FirstWord is this week polling US and EU5-based oncologists. Specifically we are asking them...


  • What percentage of adjuvant HER2-positive breast cancer patients (who have received standard 12-month therapy with trastuzumab) they estimate are eligible for further treatment?

  • How they would describe the significance of newly announced data for neratinib within the context of disease management for adjuvant HER2-positive breast cancer patients?

  • How feasible and acceptable is the suggestion that use of Imodium is expected to reduce diarrhoea rates to between 5 percent and 10 percent in a real-world setting?

  • To what percentage of adjuvant HER2-positive breast cancer patients (who have received standard 12-month therapy with trastuzumab) they would you expect to prescribe neratinib to 12 months after it becomes available?

  • To what percentage of the same patient group (in the same setting) they would expect to prescribe neratinib to three years after launch?
  • Table of Contents
    for Physician Views: Is the HER2-positive breast cancer extended adjuvant opportunity big enough to support neratinib's blockbuster forecasts? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    142 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 12% today! Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Is the HER2-positive breast cancer extended adjuvant opportunity big enough to support neratinib's blockbuster forecasts? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...